Females 0 7 0 7 B-gender
who 8 11 8 11 O
are 12 15 12 15 O
pregnant 16 24 16 24 B-pregnancy
or 25 27 25 27 O
breastfeeding 28 41 28 41 O
, 41 42 41 42 O
and 43 46 43 46 O
males 47 52 47 52 B-gender
and 53 56 53 56 I-gender
females 57 64 57 64 I-gender
who 65 68 65 68 O
can 69 72 69 72 O
not 72 75 72 75 O
comply 76 82 76 82 O
with 83 87 83 87 O
requirements 88 100 88 100 O
to 101 103 101 103 O
avoid 104 109 104 109 O
fathering 110 119 110 119 O
a 120 121 120 121 O
child 122 127 122 127 O
or 128 130 128 130 O
becoming 131 139 131 139 B-pregnancy
pregnant 140 148 140 148 I-pregnancy

Previous 0 8 149 157 O
allergic 9 17 158 166 O
reactions 18 27 167 176 O
to 28 30 177 179 O
janus 31 36 180 185 B-allergy_name
kinase 37 43 186 192 I-allergy_name
( 44 45 193 194 I-allergy_name
JAK 45 48 194 197 I-allergy_name
) 48 49 197 198 I-allergy_name
inhibitors 50 60 199 209 I-allergy_name
or 61 63 210 212 O
excipients 64 74 213 223 O

Subjects 0 8 224 232 O
must 9 13 233 237 O
be 14 16 238 240 O
able 17 21 241 245 O
to 22 24 246 248 O
discontinue 25 36 249 260 O
any 37 40 261 264 O
drug 41 45 265 269 B-treatment
treatment 46 55 270 279 I-treatment
aimed 56 61 280 285 O
at 62 64 286 288 O
lowering 65 73 289 297 O
disease 74 81 298 305 O
burden 82 88 306 312 O
in 89 91 313 315 O
CNL 92 95 316 319 B-cancer
or 96 98 320 322 O
aCML 99 103 323 327 B-cancer

Subjects 0 8 328 336 O
must 9 13 337 341 O
be 14 16 342 344 O
newly 17 22 345 350 O
diagnosed 23 32 351 360 O
or 33 35 361 363 O
previously 36 46 364 374 O
diagnosed 47 56 375 384 O
with 57 61 385 389 O
CNL 62 65 390 393 B-cancer
or 66 68 394 396 O
aCML 69 73 397 401 B-cancer

Subjects 0 8 402 410 O
must 9 13 411 415 O
be 14 16 416 418 O
willing 17 24 419 426 O
to 25 27 427 429 O
accept 28 34 430 436 O
/ 34 35 436 437 O
continue 35 43 437 445 O
transfusions 44 56 446 458 O
to 57 59 459 461 O
treat 60 65 462 467 O
low 66 69 468 471 O
hemoglobin 70 80 472 482 B-clinical_variable
levels 81 87 483 489 I-clinical_variable

Subjects 0 8 490 498 O
must 9 13 499 503 O
have 14 18 504 508 O
a 19 20 509 510 O
life 21 25 511 515 B-clinical_variable
expectancy 26 36 516 526 I-clinical_variable
of 37 39 527 529 O
> 40 41 530 531 O
6 42 43 532 533 B-lower_bound
months 44 50 534 540 I-lower_bound

Subjects 0 8 541 549 O
must 9 13 550 554 O
have 14 18 555 559 O
platelet 19 27 560 568 B-clinical_variable
count 28 33 569 574 I-clinical_variable
greater 34 41 575 582 O
than 42 46 583 587 O
25,000 47 53 588 594 B-lower_bound
per 54 57 595 598 I-lower_bound
microliter 58 68 599 609 I-lower_bound
at 69 71 610 612 O
baseline 72 80 613 621 O
and 81 84 622 625 O
at 85 87 626 628 O
the 88 91 629 632 O
start 92 97 633 638 O
of 98 100 639 641 O
study 101 106 642 647 O
( 107 108 648 649 O
day 108 111 649 652 O
1 112 113 653 654 O
, 113 114 654 655 O
cycle 115 120 656 661 O
1 121 122 662 663 O
) 122 123 663 664 O
visit 124 129 665 670 O

Subjects 0 8 671 679 O
requiring 9 18 680 689 O
therapeutic 19 30 690 701 O
doses 31 36 702 707 O
of 37 39 708 710 O
anticoagulation 40 55 711 726 B-treatment
or 56 58 727 729 O
anti 59 63 730 734 B-treatment
- 63 64 734 735 I-treatment
platelet 64 72 735 743 I-treatment
therapies 73 82 744 753 I-treatment
( 83 84 754 755 O
aspirin 84 91 755 762 B-treatment
above 92 97 763 768 O
81 98 100 769 771 B-lower_bound
mg 101 103 772 774 I-lower_bound
daily 104 109 775 780 O
, 109 110 780 781 O
Plavix 111 117 782 788 B-treatment
or 118 120 789 791 O
similar 121 128 792 799 O
agents 129 135 800 806 O
) 135 136 806 807 O
AND 137 140 808 811 O
platelet 141 149 812 820 B-clinical_variable
counts 150 156 821 827 I-clinical_variable
are 157 160 828 831 O
below 161 166 832 837 O
50,000 167 173 838 844 B-upper_bound
on 174 176 845 847 O
two 177 180 848 851 O
different 181 190 852 861 O
laboratory 191 201 862 872 O
evaluations 202 213 873 884 O
, 213 214 884 885 O
separated 215 224 886 895 O
by 225 227 896 898 O
minimum 228 235 899 906 O
of 236 238 907 909 O
two 239 242 910 913 B-lower_bound
weeks 243 248 914 919 I-lower_bound

Subjects 0 8 920 928 O
with 9 13 929 933 O
clinically 14 24 934 944 O
serious 25 32 945 952 B-chronic_disease
infections 33 43 953 963 I-chronic_disease
requiring 44 53 964 973 O
ongoing 54 61 974 981 O
antibiotic 62 72 982 992 B-treatment
therapy 73 80 993 1000 I-treatment

Subjects 0 8 1001 1009 O
with 9 13 1010 1014 O
end 14 17 1015 1018 B-chronic_disease
stage 18 23 1019 1024 I-chronic_disease
renal 24 29 1025 1030 I-chronic_disease
function 30 38 1031 1039 I-chronic_disease

Subjects 0 8 1040 1048 O
with 9 13 1049 1053 O
inadequate 14 24 1054 1064 O
liver 25 30 1065 1070 O
( 31 32 1071 1072 O
alanine 32 39 1072 1079 B-clinical_variable
aminotransferase 40 56 1080 1096 I-clinical_variable
[ 57 58 1097 1098 I-clinical_variable
ALT]/serum 58 68 1098 1108 I-clinical_variable
glutamate 69 78 1109 1118 I-clinical_variable
pyruvate 79 87 1119 1127 I-clinical_variable
transaminase 88 100 1128 1140 I-clinical_variable
[ 101 102 1141 1142 I-clinical_variable
SGPT 102 106 1142 1146 I-clinical_variable
] 106 107 1146 1147 I-clinical_variable
above 108 113 1148 1153 O
4 114 115 1154 1155 B-lower_bound
X 116 117 1156 1157 I-lower_bound
upper 118 123 1158 1163 I-lower_bound
limit 124 129 1164 1169 I-lower_bound
of 130 132 1170 1172 I-lower_bound
normal 133 139 1173 1179 I-lower_bound
[ 140 141 1180 1181 I-lower_bound
ULN 141 144 1181 1184 I-lower_bound
] 144 145 1184 1185 I-lower_bound
or 146 148 1186 1188 O
direct 149 155 1189 1195 B-clinical_variable
bilirubin 156 165 1196 1205 I-clinical_variable
4 166 167 1206 1207 O
X 168 169 1208 1209 O
ULN 170 173 1210 1213 O
AND 174 177 1214 1217 O
the 178 181 1218 1221 O
lab 182 185 1222 1225 O
abnormalities 186 199 1226 1239 O
are 200 203 1240 1243 O
felt 204 208 1244 1248 O
to 209 211 1249 1251 O
be 212 214 1252 1254 O
due 215 218 1255 1258 O
to 219 221 1259 1261 O
underlying 222 232 1262 1272 O
liver 233 238 1273 1278 B-chronic_disease
dysfunction 239 250 1279 1290 I-chronic_disease
) 250 251 1290 1291 O

Subjects 0 8 1292 1300 O
with 9 13 1301 1305 O
invasive 14 22 1306 1314 O
malignancy 23 33 1315 1325 B-cancer
over 34 38 1326 1330 O
the 39 42 1331 1334 O
previous 43 51 1335 1343 B-upper_bound
2 52 53 1344 1345 I-upper_bound
years 54 59 1346 1351 I-upper_bound
except 60 66 1352 1358 O
treated 67 74 1359 1366 O
early 75 80 1367 1372 O
stage 81 86 1373 1378 O
carcinomas 87 97 1379 1389 B-cancer
of 98 100 1390 1392 I-cancer
the 101 104 1393 1396 I-cancer
skin 105 109 1397 1401 I-cancer
, 109 110 1401 1402 O
completely 111 121 1403 1413 O
resected 122 130 1414 1422 O
intraepithelial 131 146 1423 1438 O
carcinoma 147 156 1439 1448 B-cancer
of 157 159 1449 1451 I-cancer
the 160 163 1452 1455 I-cancer
cervix 164 170 1456 1462 I-cancer
, 170 171 1462 1463 O
and 172 175 1464 1467 O
completely 176 186 1468 1478 O
resected 187 195 1479 1487 O
papillary 196 205 1488 1497 B-cancer
thyroid 206 213 1498 1505 I-cancer
and 214 217 1506 1509 O
follicular 218 228 1510 1520 B-cancer
thyroid 229 236 1521 1528 I-cancer
cancers 237 244 1529 1536 I-cancer

Subjects 0 8 1537 1545 O
with 9 13 1546 1550 O
known 14 19 1551 1556 O
diagnosis 20 29 1557 1566 O
of 30 32 1567 1569 O
human 33 38 1570 1575 B-chronic_disease
immunodeficiency 39 55 1576 1592 I-chronic_disease
virus 56 61 1593 1598 I-chronic_disease
( 62 63 1599 1600 I-chronic_disease
HIV 63 66 1600 1603 I-chronic_disease
) 66 67 1603 1604 I-chronic_disease
or 68 70 1605 1607 O
chronic 71 78 1608 1615 B-chronic_disease
active 79 85 1616 1622 I-chronic_disease
Hepatitis 86 95 1623 1632 I-chronic_disease
B 96 97 1633 1634 I-chronic_disease
or 98 100 1635 1637 O
C 101 102 1638 1639 B-chronic_disease

Subjects 0 8 1640 1648 O
with 9 13 1649 1653 O
severe 14 20 1654 1660 O
( 21 22 1661 1662 O
immediately 22 33 1662 1673 O
life 34 38 1674 1678 O
threatening 39 50 1679 1690 O
) 50 51 1690 1691 O
and 52 55 1692 1695 O
recent 56 62 1696 1702 O
( 63 64 1703 1704 O
occurring 64 73 1704 1713 O
within 74 80 1714 1720 O
the 81 84 1721 1724 O
last 85 89 1725 1729 B-upper_bound
3 90 91 1730 1731 I-upper_bound
months 92 98 1732 1738 I-upper_bound

Taking 0 6 1739 1745 O
investigational 7 22 1746 1761 B-treatment
or 23 25 1762 1764 O
commercial 26 36 1765 1775 B-treatment
agents 37 43 1776 1782 I-treatment
or 44 46 1783 1785 O
therapies 47 56 1786 1795 B-treatment
with 57 61 1796 1800 O
the 62 65 1801 1804 O
intent 66 72 1805 1811 O
to 73 75 1812 1814 O
treat 76 81 1815 1820 O
the 82 85 1821 1824 O
subject 86 93 1825 1832 O
's 93 95 1832 1834 O
malignancy 96 106 1835 1845 B-cancer
other 107 112 1846 1851 O
than 113 117 1852 1856 O
those 118 123 1857 1862 O
therapies 124 133 1863 1872 O
permitted 134 143 1873 1882 O

all 0 3 1883 1886 O
patients 4 12 1887 1895 O
must 13 17 1896 1900 O
have 18 22 1901 1905 O
a 23 24 1906 1907 O
bone 25 29 1908 1912 O
marrow 30 36 1913 1919 O
biopsy 37 43 1920 1926 B-treatment
completed 44 53 1927 1936 O
during 54 60 1937 1943 O
the 61 64 1944 1947 O
screening 65 74 1948 1957 O
or 75 77 1958 1960 O
baseline 78 86 1961 1969 O
period 87 93 1970 1976 O
if 94 96 1977 1979 O
one 97 100 1980 1983 O
has 101 104 1984 1987 O
not 105 108 1988 1991 O
been 109 113 1992 1996 O
done 114 118 1997 2001 O
within 119 125 2002 2008 O
90 126 128 2009 2011 B-upper_bound
days 129 133 2012 2016 I-upper_bound
of 134 136 2017 2019 O
day 137 140 2020 2023 O
1 141 142 2024 2025 O
, 142 143 2025 2026 O
cycle 144 149 2027 2032 O
one 150 153 2033 2036 O

cardiac 0 7 2037 2044 B-chronic_disease
dysfunction 8 19 2045 2056 I-chronic_disease

creatinine 0 10 2057 2067 B-clinical_variable
clearance 11 20 2068 2077 I-clinical_variable
[ 21 22 2078 2079 I-clinical_variable
CrCl 22 26 2079 2083 I-clinical_variable
] 26 27 2083 2084 I-clinical_variable
< 28 29 2085 2086 O
15 30 32 2087 2089 B-upper_bound
mL 33 35 2090 2092 I-upper_bound
/ 35 36 2092 2093 I-upper_bound
min 36 39 2093 2096 I-upper_bound
or 40 42 2097 2099 O
glomerular 43 53 2100 2110 B-clinical_variable
filtration 54 64 2111 2121 I-clinical_variable
rate 65 69 2122 2126 I-clinical_variable
[ 70 71 2127 2128 I-clinical_variable
GFR 71 74 2128 2131 I-clinical_variable
] 74 75 2131 2132 I-clinical_variable
< 76 77 2133 2134 O
15 77 79 2134 2136 O
mL 80 82 2137 2139 O
/ 82 83 2139 2140 O
min 83 86 2140 2143 O

esophageal 0 10 2144 2154 B-chronic_disease
variceal 11 19 2155 2163 I-chronic_disease
bleeding 20 28 2164 2172 I-chronic_disease

for 0 3 2173 2176 O
drugs 4 9 2177 2182 O
that 10 14 2183 2187 O
have 15 19 2188 2192 O
more 20 24 2193 2197 O
long 25 29 2198 2202 O
- 29 30 2202 2203 O
lasting 30 37 2203 2210 O
effects 38 45 2211 2218 O
on 46 48 2219 2221 O
the 49 52 2222 2225 O
marrow 53 59 2226 2232 O
, 59 60 2232 2233 O
such 61 65 2234 2238 O
as 66 68 2239 2241 O
thalidomide 69 80 2242 2253 B-treatment
and 81 84 2254 2257 O
its 85 88 2258 2261 O
analogs 89 96 2262 2269 O
, 96 97 2269 2270 O
and 98 101 2271 2274 O
interferon 102 112 2275 2285 B-treatment
, 112 113 2285 2286 O
subjects 114 122 2287 2295 O
should 123 129 2296 2302 O
discontinue 130 141 2303 2314 O
these 142 147 2315 2320 O
no 148 150 2321 2323 O
later 151 156 2324 2329 O
than 157 161 2330 2334 O
day 162 165 2335 2338 B-upper_bound
-28 166 169 2339 2342 I-upper_bound

hemorrhagic 0 11 2343 2354 B-chronic_disease
strokes 12 19 2355 2362 I-chronic_disease

intracranial 0 12 2363 2375 B-chronic_disease
hemorrhage 13 23 2376 2386 I-chronic_disease

pulmonary 0 9 2387 2396 B-chronic_disease
dysfunction 10 21 2397 2408 I-chronic_disease

subjects 0 8 2409 2417 O
should 9 15 2418 2424 O
discontinue 16 27 2425 2436 O
hydroxyurea 28 39 2437 2448 B-treatment
to 40 42 2449 2451 O
treat 43 48 2452 2457 O
underlying 49 59 2458 2468 O
CNL 60 63 2469 2472 B-cancer
or 64 66 2473 2475 O
aCML 67 71 2476 2480 B-cancer
disease 72 79 2481 2488 I-cancer
no 80 82 2489 2491 O
later 83 88 2492 2497 O
than 89 93 2498 2502 O
day 94 97 2503 2506 B-upper_bound
-7 98 100 2507 2509 I-upper_bound
( 101 102 2510 2511 O
one 102 105 2511 2514 B-upper_bound
week 106 110 2515 2519 I-upper_bound
before 111 117 2520 2526 I-upper_bound
starting 118 126 2527 2535 O
ruxolitinib 127 138 2536 2547 B-treatment
) 138 139 2547 2548 O

subjects 0 8 2549 2557 O
with 9 13 2558 2562 O
a 14 15 2563 2564 O
history 16 23 2565 2572 O
of 24 26 2573 2575 O
Hepatitis 27 36 2576 2585 B-chronic_disease
B 37 38 2586 2587 I-chronic_disease
and/or 39 45 2588 2594 I-chronic_disease
C 46 47 2595 2596 I-chronic_disease
are 48 51 2597 2600 O
allowed 52 59 2601 2608 O
on 60 62 2609 2611 O
trial 63 68 2612 2617 O
if 69 71 2618 2620 O
the 72 75 2621 2624 O
virus 76 81 2625 2630 O
is 82 84 2631 2633 O
undetected 85 95 2634 2644 O
at 96 98 2645 2647 O
the 99 102 2648 2651 O
time 103 107 2652 2656 O
of 108 110 2657 2659 O
enrollment 111 121 2660 2670 O

